GRAIL Partners With Professional Golfers Steve Stricker and Juli Inkster to Raise Awareness of Multi-Cancer Early Detection at Second Annual Galleri Classic PGA TOUR Champions Tournament
- None.
- None.
Collaboration Will Continue to Raise Awareness of the Galleri® Multi-Cancer Early Detection Test, a New Proactive Tool in Finding Cancer Earlier
Portion of Galleri Classic Proceeds Will be Directed to Local Cancer-related Nonprofit Organizations Focused on Underserved Populations in the Coachella Valley
Stricker — a 12-time PGA TOUR winner — will again be playing in the Galleri Classic. As part of his record-setting year on the PGA TOUR Champions in 2023, Stricker tied for fifth place in the inaugural tournament.
“I know from personal experience what it’s like to be caught off-guard by health concerns and how important it is to take proactive care of myself, especially as I’ve gotten older,” said Stricker. “I encourage others at elevated risk of cancer to speak with their doctor about adding the Galleri test into their routine care.”
Inkster, an LPGA and World Golf Hall of Fame member and 31-time winner on the LPGA Tour, including seven major championships, will be collaborating with GRAIL for a second year. After losing her father to late-stage esophageal and liver cancer, cancer screening is a cause close to her heart.
Proceeds from the tournament will fund local cancer-related nonprofit organizations focused on underserved populations. The tournament will support the six charitable partners announced in 2023, including the American Cancer Society (
“We are honored to continue our support of six organizations in the Coachella Valley working tirelessly to help those affected by cancer,” said Bob Ragusa, Chief Executive Officer at GRAIL. “Cancer remains a leading cause of death worldwide, and by partnering with those who share our commitment, we can make a meaningful difference across the cancer continuum.”
Single-cancer screenings play an important role in detecting five specific cancers today. However, nearly
Cancers growing in the body shed DNA into the bloodstream. Galleri can identify DNA shed by cancer cells while the patient is still asymptomatic, when it can be more easily treated and is potentially curable. Data from the National Cancer Institute demonstrated that finding cancer early improves overall 5-year survival rates from approximately
Galleri, a prescription-only test, is recommended for people over the age of 50, or those with an elevated risk of cancer.
About GRAIL
GRAIL is a healthcare company whose mission is to detect cancer early, when it can be cured. GRAIL is focused on alleviating the global burden of cancer by developing pioneering technology to detect and identify multiple deadly cancer types early. The company is using the power of next-generation sequencing, population-scale clinical studies, and state-of-the-art computer science and data science to enhance the scientific understanding of cancer biology, and to develop its multi-cancer early detection blood test. GRAIL is headquartered in
For more information, visit grail.com.
About Galleri®
The Galleri multi-cancer early detection test can detect a signal shared by more than 50 types of cancer, as defined by the American Joint Committee on Cancer Staging Manual, through a routine blood draw. When a cancer signal is detected, the Galleri test predicts the cancer signal origin, or the tissue or organ associated with the cancer signal, with high accuracy to help guide the next steps to diagnosis. The Galleri test requires a prescription from a licensed health care provider and should be used in addition to recommended cancer screenings such as mammography, colonoscopy, prostate-specific antigen (PSA) test, or cervical cancer screening. It is recommended for use in adults with an elevated risk for cancer, such as those aged 50 or older.
For more information about Galleri, visit galleri.com.
Important Galleri Safety Information
The Galleri test is recommended for use in adults with an elevated risk for cancer, such as those aged 50 or older. The Galleri test does not detect all cancers and should be used in addition to routine cancer screening tests recommended by a healthcare provider. Galleri is intended to detect cancer signals and predict where in the body the cancer signal is located. Use of Galleri is not recommended in individuals who are pregnant, 21 years old or younger, or undergoing active cancer treatment.
Results should be interpreted by a healthcare provider in the context of medical history, clinical signs and symptoms. A test result of “No Cancer Signal Detected” does not rule out cancer. A test result of “Cancer Signal Detected” requires confirmatory diagnostic evaluation by medically established procedures (e.g., imaging) to confirm cancer.
If cancer is not confirmed with further testing, it could mean that cancer is not present or testing was insufficient to detect cancer, including due to the cancer being located in a different part of the body. False-positive (a cancer signal detected when cancer is not present) and false-negative (a cancer signal not detected when cancer is present) test results do occur. Rx only.
Laboratory/Test Information
GRAIL’s clinical laboratory is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) and accredited by the College of American Pathologists. The Galleri test was developed, and its performance characteristics were determined by GRAIL. The Galleri test has not been cleared or approved by the
View source version on businesswire.com: https://www.businesswire.com/news/home/20240130059243/en/
For GRAIL
Corporate Communications
Kristen Davis
Cammy Duong
pr@grail.com
Investor Relations
Alex Dobbin
ir@grail.com
Source: GRAIL, LLC
FAQ
What is the Galleri Classic?
Who is GRAIL, LLC partnering with for the Galleri Classic?
Where will the proceeds from the Galleri Classic be directed?
When is the Galleri Classic taking place?
Who will be playing in the Galleri Classic?
